Survival analysis of single agent gemcitabine therapy in patients with metastatic breast cancer

Aim: Gemcitabine has demonstrated experimental and clinical antitumor activity in various human neoplasms including pancreas,ovary, non-small cell lung and breast tumors. We aimed to investigate the factors affecting progression-free survival (PFS) andoverall survival (OS) of patients who received single agent gemcitabine for metastatic breast cancer.Material Methods: Twenty-eight patients with metastatic breast cancer who were treated with gemcitabine in Gaziantep UniversityMedical Faculty Medical Oncology Department between March 2007 and December 2018 were evaluated retrospectively. Gemcitabine1000 mg / m2 was administered as a single agent treatment on the 1st and 8th days, every 21 days.Results: Twenty-seven (96.4%) of the patients were female and 1 (3.6%) was male. The median age was 52 years(range 35-76).Median PFS was 5 months (95% confidence interval 2,41-7,58) and median OS was 26 months (95% confidence interval 11,73-40,26). The median PFS of the patients with only lung metastasis was 16 months and the other patients were 4 months (Log-rankp = 0.020)Conclusion: Gemcitabine is a very well tolerated agent with sufficient efficacy for patients with metastatic breast cancer who werepreferred to use single agent chemotherapy than combination therapies. Patients with only lung metastasis may benefit more fromsingle agent gemcitabine in metastatic breast cancer.

PDF

___

1- American Cancer Society. Cancer Facts and Figures 2017. Atlanta:American Cancer Society;2017.
2- Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 2004;9:617-32.
3- Early Breast Cancer Trialists’ Collaborative Group. Comparisons between different polychemotherapy regimens for early breast cancer:meta-analyses of longterm outcome among 100 000 women in 123 randomised trials. Lancet 2012;379:432-44
4- Vernieri C, Prisciandaro M, Milano M, et al. single agent gemcitabine vs. carboplatin-gemcitabine in advanced breast cancer: a retrospective comparison of efficacy and safety profiles. Clin Breast Cancer. 2019;19:306- 18.
5- Kaye SB. Gemcitabine: current status of phase I and II trials. J Clin Oncol 1994;12:1527-31.
6- Brodowicz T, Kostler WJ, Möslinger R, et al. Single-agent gemcitabine as second and third line treatment in metastatic breast cancer. Breast 2000;9:338-42
7- Dear RF, McGeechan K, Jenkins MC, et al. Wilcken Combination versus sequential single agent chemotherapy for metastatic breast cancer Cochrane Database Syst Rev 2013;12:CD008792
8- Spielmann M, Llombart-Cussac A, Kalla S, et al.Singleagent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001;60:303-7
9- C.H. Smorenburg, M. Bontenbal, C. Seynaeve, et al.Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 2001;66:83-7.
10- Weibing Li, Hongbiao Wang, Xuyuan Li. Efficacy of gemcitabine-based chemotherapy in metastatic breast cancer: a meta-analysis of randomized controlled trials, Curren Med Res Opinion 2013;11:1443-52.
11- Qian Hu, Jun-xia Jiang, Long Luo, et al. A systematic review of gemcitabine and taxanes combination therapy randomized trials for metastatic breast cancer. Springer Plus 2014;3:293.
12- Sezgin C, Karabulut B, Uslu R, ve ark. Daha önceden antrasiklin ve taksan tedavisi almış metastatik meme kanserli hastalarda gemsitabin tedavisi. THOD 2005:2;15
13- Schmid P, Akrivakis K, Flath B, et al. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 1999;10:625-31.